Pfizer COVID-19 Vaccine Found to be More than 90 Percent Effective
This week, Pfizer and BioNTech announced their vaccine candidate was found to be more than 90 percent effective in preventing COVID-19 in participants without evidence of prior COVID-19 infection in the first interim efficacy analysis. The study enrolled 43,538 participants and evaluated 94 confirmed COVID-19 cases in trial participants. No serious safety concerns were observed during the interim efficacy analysis, and submission to the U.S. Food and Drug Administration (FDA) for emergency use authorization (EUA) is planned for the third week of November.
The clinical trial will continue through its final analysis of 164 confirmed cases in order to collect further data and characterize the vaccine candidate’s performance against other study endpoints. A full announcement from Pfizer and BioNTech is available here.